Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Selling Direct To Canadian Pharmacies, Auditing Orders To Curb Imports

Executive Summary

GlaxoSmithKline is selling its products direct to pharmacies in Canada that are suspected by the company of selling to consumers in the U.S

You may also be interested in...



Medicare Rx Fallback Plan Would Be More Likely Under Sen. Kennedy Bill

Government-sponsored Medicare prescription drug fallback plans would be more widely available under a bill introduced by Sen. Edward Kennedy (D-Mass.)

Medicare Rx Fallback Plan Would Be More Likely Under Sen. Kennedy Bill

Government-sponsored Medicare prescription drug fallback plans would be more widely available under a bill introduced by Sen. Edward Kennedy (D-Mass.)

AARP Supports Canadian Imports To Place “Downward Pressure” On Rx Costs

AARP is endorsing prescription drug reimportation from Canada as a measure to help control the cost of drugs

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel